生物来源

human prostate

抗体应用

cell culture | mammalian: suitable

免责声明

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form. Additionally, any recipient wanting to use the cell line in the field of vaccines for the treatment or prevention of prostate cancer should first obtain permission from GemVax & KAEL Co., Ltd. Contact : Dr. Eujin Hyun, Head of R&D Department (eujinhyun@kaelgemvax.com).

其他说明

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

传代培养常规

Split sub-confluent cultures (70-80%) 1:4 to 1:10 seeding at approximately 3 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37 °C. It is important to inactivate the trypsin with an equal volume of trypsin inhibitor (the culture medium contains too low a serum content to inactivate the trypsin). To remove all traces of trypsin and trypsin inhibitor pellet the cells by centrifugation and resuspend the cells in fresh medium. Media change every second day.

培养基

Stemline Keratinocyte Medium II (Sigma S0196) + Stemline Keratinocyte Growth Supplement (Sigma S9945) + 2 mM Glutamine + 2% Fetal Bovine Serum (FBS). Addition of 2% serum was found to increase cell viability.

细胞系来源

Prostate cancer well differentiated, early stage

DNA图谱分析

STR-PCR Data: Amelogenin: X CSF1PO: 12 D13S317: 11 D16S539: 11 D5S818: 12 D7S820: 7,8 THO1: 7,9.3 TPOX: 8 vWA: 17,19